Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher

Earum Pharmaceuticals | The company has signed digital MOU with Government of Gujarat. It is planning to make an investment of approximate Rs 50 crore by establishing manufacturing unit of pharma finished formulation/ API.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Prabhudas Lilladher has come out with its third quarter (October-December’ 21) earnings estimates for the Pharma sector. The brokerage house expects Ipca Laboratories to report net profit at Rs 179.6 crore down 32.4% year-on-year (down 28.2% quarter-on-quarter).

Net Sales are expected to decrease by 2.2 percent Y-o-Y (down 10.8 percent Q-o-Q) to Rs 1,378.3 crore, according to Prabhudas Lilladher.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 27.2 percent Y-o-Y (down 23.9 percent Q-o-Q) to Rs 263.5 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More